Trial data suggests retatrutide produces greater weight loss than tirzepatide (24.2% vs 20.9%) or semaglutide (24.2% vs 14.9%)
This ensures the substance is actually Retatrutide and not a cheaper alternative like Semaglutide
"These peptides help create insulin sensitivity," Juls explains
The presence of multiple similar domain names raises questions about brand consistency
During early treatment, many people find they cannot tolerate hot foods, large portions, or high-fat meals
Challenges include gastrointestinal side effects, nutritional deficiencies due to calorie reduction, muscle and bone loss, low long-term adherence with subsequent weight regain, and high costs, resulting in low cost-effectiveness